The global liver cancer diagnostics market value was US$ 9.7 billion in 2020. The global liver cancer diagnostics market value is forecast to reach US$ 20.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 8% during the forecast period from 2021-2030.
Cancer of the liver begins in the cells of the liver. Several types of cancer can occur in the liver. Hepatocellular carcinoma is the most common type of liver cancer, which begins in the main liver cell type (hepatocyte). Hepatoblastoma and intrahepatic cholangiocarcinoma are less common types of liver cancer.
Factors Influencing Market Growth
A surge in government initiatives and other private organizations focused on promoting early diagnosis and prevention of liver cancer is forecast to spur global market growth in the coming years.
Increasing costs of technologically advanced liver cancer diagnostic solutions may slow down the global market growth.
The increase of technological advancements enabling better imaging of cancerous cells, improvements in equipment to identify the type of liver cancer, and increased efficiency of results will help the global liver cancer diagnostics market grow during the forecast period.
Impact Analysis of COVID-19
The COVID-19 pandemic had a negative effect on the global liver cancer diagnostics market. A fall in the number of patients visiting cancer hospitals and clinics due to the pandemic has greatly affected revenues, as has a change in care approach for emergency cases and critically ill COVID-19 patients. As a result of COVID-19, hospital visits for liver cancer diagnostics have decreased. It is mainly because of the low number of healthcare professionals available in the country.
Regional Insights
In 2020, North America accounted for the largest revenue share of the liver cancer diagnostics market, and it is forecast to remain dominant throughout the forecast period. Health insurance policies, well-established infrastructure, and the use of innovative diagnostic tests account for the region's dominance. Additionally, the local presence of leading players and their ongoing strategic initiatives contribute to regional growth. As a result of the high prevalence of hepatocellular carcinoma in North America, the U.S. dominates the market share.
Over the study period, liver cancer diagnostics is forecast to display the highest growth in the Asia Pacific. Due to the high prevalence of Hepatitis in emerging countries like India and China, this growth is high. Further, government initiatives to increase awareness about early detection of liver cancer and rising consumption of alcohol and tobacco contribute to market growth.

Leading Competitors
The leading prominent companies profiled in the global liver cancer diagnostics market are:
Abbott Laboratories
Becton Dickinson & Company
Epigenomics AG
F. Hoffmann-La Roche Ltd.
Fujifilm Medical Systems U.S.A., Inc.
Illumina, Inc.
Koninklijke Philips N.V.
Qiagen N.V.
Siemens Healthineers
Thermo Fisher Scientific, Inc.
Other Prominent Players
Scope of the Report
The global liver cancer diagnostics market segmentation focuses on Test Type, End-use, and Region.
Segmentation based on Test Type
Laboratory Tests
o Biomarkers
? Oncofetal and Glycoprotein Antigens
? Enzymes and Isoenzymes
? Growth Factors and Receptors
? Molecular Markers
? Pathological Biomarkers
o Blood Tests
Imaging Tests
Endoscopy
Biopsy
Others
Segmentation based on End-Use
Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Pharmaceutical & CRO Laboratories
Segmentation based on Region
North America
o The U.S.
o Canada
o Mexico
Europe
? Western Europe
o The UK
o Germany
o France
o Italy
o Spain
o Rest of Western Europe
? Eastern Europe
o Poland
o Russia
o Rest of Eastern Europe
Asia Pacific
o China
o India
o Japan
o Australia & New Zealand
o ASEAN
o Rest of Asia Pacific
Middle East & Africa (MEA)
o UAE
o Saudi Arabia
o South Africa
o Rest of MEA
South America
o Brazil
o Argentina
o Rest of South America


Meta Title: Liver Cancer Diagnostics Market Size, Share, Trends and Forecast Till 2030

Meta Description: The global liver cancer diagnostics market value is forecast to reach US$ 20.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 8% during the forecast period from 2021-2030.
Meta Keywords: Liver Cancer Diagnostics Market, Liver Cancer Diagnostics Market Share, Liver Cancer Diagnostics Market Size, Liver Cancer Diagnostics Market Trends, Liver Cancer Diagnostics Market Insights, Liver Cancer Diagnostics Market Forecast